List of Studies ( Metabolite:Phenolsulfonphthalein)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004291 | AN007136 | Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004290 | AN007134 | Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004194 | AN006967 | PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003906 | AN006411 | Neither Plasmodium falciparum Plasmepsin Copy Number Nor Piperaquine Treatment Impact Hemoglobin Digestion | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST003642 | AN005981 | Hexosamine Biosynthesis Disruption Impairs GPI Production and Arrests Plasmodium falciparum Growth at Schizont Stages | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST003565 | AN005858 | Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Brain | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Heart | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005645 | Pharmacokinetics of Fasnall in NSG mice | Liver | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003435 | AN005643 | Metabolomics analysis of zebrafish embryos treated with rotenone, Fasnall, TVB-2640, and GSK2194069 | Media | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003434 | AN005641 | Plasma concentrations of Fasnall in mice after a bolus of 10 mg/kg administered intraperitoneally. | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003433 | AN005639 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate, Fasnall, and GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003432 | AN005637 | Intracellular and medium metabolomics of BT-474 cells treated with LW6 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003431 | AN005635 | Metabolomics analysis of breast cancer cell lines treated with dimethylmalonate (DMM), GSK2194069, and their combination. | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003430 | AN005633 | Intracellular and medium metabolomics of BT-474 cells treated with GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003429 | AN005631 | Intracellular and medium metabolomics of BT-474 cells treated with Fasnall that was manufactured by Enamine | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005629 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005627 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003412 | AN005604 | Intracellular and medium metabolomics for BT-474 cells treated with cerulenin, TVB-2640, and TVB-3166 for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003411 | AN005602 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h (C75 MRM included) | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003367 | AN005518 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003366 | AN005516 | Malate dehydrogenase (MDH) inhibition assay: Fasnall does not affect MDH activity in vitro | Synthetic | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003365 | AN005514 | Intracellular and medium metabolomics for BT-474 breast cancer cells treated with a range of Fasnall and GSK2194069 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003224 | AN005286 | The Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD0156 is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase and is an Attractive Candidate for Repositioning Against Malaria | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST003179 | AN005222 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003160 | AN005185 | New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003144 | AN005160 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003066 | AN005022 | Heritability of RBC metabolites: baseline correlation of metabolites and markers of RBC health and stability | Erythrocytes | Human | University of Iowa | Other | |
| ST002926 | AN004799 | Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002809 | AN004568 | Role of cilia in mitochondrial function | Cultured cells | Dog | Kidney disease | Medical University of South Carolina | LC-MS |
| ST002809 | AN004568 | Role of cilia in mitochondrial function | Cultured cells | Mouse | Kidney disease | Medical University of South Carolina | LC-MS |
| ST002792 | AN004543 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002555 | AN004207 | Ethnicity-Specific Differences in Ovarian Cancer Metabolic Signatures | Cultured cells | Human | Cancer | University of Oklahoma Health Sciences Center | LC-MS |
| ST002322 | AN003789 | Metabolomics study comparing SCAP KO and WT B cells | Cultured cells | Mouse | Indiana University School of Medicine | LC-MS | |
| ST002234 | AN003644 | A metabolic map of the DNA damage response identifies PRDX1 in nuclear ROS scavenging and aspartate synthesis | Cultured cells | Human | DNA damage response | CRG | LC-MS |
| ST002108 | AN003449 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002107 | AN003447 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002106 | AN003445 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002104 | AN003439 | Chemoresistant Cancer Cell Lines are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations | Cultured cells | Human | Cancer | Future Industries Institute | LC-MS |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST002078 | AN003387 | Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target. | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002078 | AN003388 | Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target. | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002078 | AN003389 | Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target. | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002078 | AN003390 | Multiple modes of interfering with the activity of Plasmodium falciparum cytoplasmic isoleucyl-tRNA synthetase illustrate the enzyme is a promising antimalarial target. | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002024 | AN003294 | Plasmodium falciparum stable-isotope carbon labeling to explore metabolic consequences of keto–acid dehydrogenase disruption | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002011 | AN003277 | The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases. | Blood | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002011 | AN003278 | The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases. | Blood | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002011 | AN003279 | The anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases. | Blood | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST002010 | AN003276 | Chemoresistant Ovarian Cancer Global Metabolomics | Cultured cells | Human | Cancer | University of South Australia | LC-MS |
| ST001985 | AN003236 | Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183 | Blood | Human | Malaria | Pennsylvania State University | LC-MS |
| ST001985 | AN003236 | Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183 | Blood | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001985 | AN003236 | Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183 | Cultured cells | Human | Malaria | Pennsylvania State University | LC-MS |
| ST001985 | AN003236 | Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183 | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001983 | AN003234 | Metabolomic Fingerprinting of Human High Grade Serous Ovarian Carcinoma Cell Lines | Ovarian cancer cells | Human | Cancer | University of Oklahoma Health Sciences Center | LC-MS |
| ST001835 | AN002977 | Use of Integrated Metabolomics, Transcriptomics, and Signal Protein Profile to Characterize the Effector Function and Associated Metabotype of Polarized Macrophage Phenotypes | Blood | Human | Idaho Veterans Research and Education Foundation | LC-MS | |
| ST001788 | AN002899 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | LC-MS | |
| ST001788 | AN002900 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | LC-MS | |
| ST001660 | AN002711 | Plasmodium falciparum metabolomics as a result of treatment with putative acetyl-CoA synthetase inhibitors | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001549 | AN002580 | β-Adrenergic regulation of metabolism in macrophages (part-III) | Macrophages | Human | Monash University | LC-MS | |
| ST001548 | AN002579 | β-Adrenergic regulation of metabolism in macrophages (part-II) | Macrophages | Human | Monash University | LC-MS | |
| ST001547 | AN002577 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | LC-MS | |
| ST001384 | AN002309 | Plasmodium falciparum increased time in circulation underlies persistent asymptomatic infection in the dry season | Blood | Human | Malaria | Pennsylvania State University | LC-MS |
| ST001304 | AN002172 | Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii | Fibroblast cells | Toxoplasma gondii | Parasitic infection | Monash University | LC-MS |
| ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001232 | AN002050 | Combining stage - specificity and metabolomic profiling to advance drug discovery for malaria | Cultured cells | Plasmodium falciparum | Malaria | Pennsylvania State University | LC-MS |
| ST001205 | AN002007 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001205 | AN002007 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001204 | AN002005 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001204 | AN002005 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001202 | AN002001 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001202 | AN002001 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001175 | AN001950 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000976 | AN001597 | GC6-74 matabolomic of TB (Part 3: Plasma_RPMI) | Blood | Human | Tuberculosis | Max Planck Institute for Infection Biology | LC-MS |
| ST000974 | AN001595 | GC6-74 matabolomic of TB (Part 1: Plasma) | Blood | Human | Tuberculosis | Max Planck Institute for Infection Biology | LC-MS |
| ST000546 | AN000833 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000539 | AN000819 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash University | LC-MS | |
| ST000403 | AN000643 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences | LC-MS | |
| ST000242 | AN000378 | Whole unconditioned medium (Defined culture media, M199),Whole M1 medium,Whole M2 medium | Macrophages | Human | Mayo Clinic | LC-MS |
